Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Eosinophilic Esophagitis

Eosinophilic Esophagitis

Part of Esophageal Diseases

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Eosinophilic Esophagitis

34 trials tracked for Eosinophilic Esophagitis: 12 in phase 3 or 4 and 6 with published results. The most-cited published study has 555 citations.

34Trials tracked
12Phase 3 & 4
0Recruiting
6With published results
Phase distribution
Phase 4 4 Phase 3 8 Phase 2 11 Phase 1 1 Other / NA 10
  1. Phase 3 Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years Completed · 555 cited
  2. Phase 4 Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis Completed · 196 cited
  3. Phase 4 Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis Completed · 40 cited
  4. Phase 3 Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE) Completed · 26 cited
  5. Phase 3 A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis Completed · 16 cited
  6. Phase 4 Efficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic Esophagitis Completed · 3 cited
Show 28 more trials
  1. Phase 4 Cycling of Topical Steroids for Treatment of EoE (Eosinopilic Esophagitis) Completed
  2. Phase 3 Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis Completed
  3. Phase 3 Eosinophilic Esophagitis Intervention Trial-1 Food vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids Completed
  4. Phase 3 A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis Completed
  5. Phase 3 Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis Completed
  6. Phase 3 The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis Completed
  7. Phase 2 Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE) Completed
  8. Phase 2 An Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) Completed
  9. Phase 2 A Study to Assess the Safety and Efficacy of Oral Etrasimod in Adult Participants With Eosinophilic Esophagitis Completed
  10. Phase 2 Topical Steroid Treatment for Eosinophilic Esophagitis Completed
  11. Phase 2 Milk Patch for Eosinophilic Esophagitis Completed
  12. Phase 2 Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE) Completed
  13. Phase 2 A Study of Flovent in Patients With Eosinophilic Esophagitis Completed
  14. Phase 2 Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis Completed
  15. Phase 2 Mepo for Eosinophilic Esophagitis (EoE) Study Completed
  16. Phase 2 Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD Completed
  17. Phase 2 A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis Completed
  18. Phase 1 Comparing the Availability of AQ280 in the Body After Single Oral Doses of a Capsule Formulation Versus a Tablet for Oral Suspension Formulation Completed
  19. N/A Identification of Autoantigens in EGPA and Severe Eosinophilic Asthma Completed
  20. N/A Value of Patch Testing in Direct Diet Therapy for Eosinophilic Esophagitis Completed
  21. N/A Mucosal Impedance and Eosinophilic Esophagitis Completed
  22. N/A Topical Budesonide Treatment for Eosinophilic Esophagitis (EoE) Completed
  23. N/A Comparing Anesthetic Techniques in Children Having Esophagogastroduodenoscopies Completed
  24. N/A Application of a Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy in Patients With Eosinophilic Esophagitis (IDiET) Completed
  25. N/A Cytosponge and Dietary Therapy in EoE Completed
  26. N/A Study to Image the Esophagus Using the OFDI Capsule Completed
  27. N/A Use of Esophageal String Test to Understand Symptoms, Inflammation, and Function in Eosinophilic Esophagitis Completed
  28. N/A Fluticasone Versus Esomeprazole to Treat Eosinophilic Esophagitis Completed

Showing the 34 most-cited and recently-updated of 34 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Eosinophilic Esophagitis: what the trials found

New evidence indicates that CC-93538 is associated with a significant reduction in mean Dysphagia Days at week 24 9 and a significantly higher percentage of patients achieving peak esophageal eosinophil counts of 6/Hpf compared to placebo at both week 24 and week 48 9. Additionally, CC-93538 is associated with new clinical data in Phase 3 trials 1.

Dupilumab has demonstrated significant efficacy in reducing peak esophageal intraepithelial eosinophil counts (p < 0.0001) and improving Dysphagia Symptom Questionnaire (DSQ) scores (p = 0.0004) 8. In a separate study, Dupilumab was associated with a statistically significant reduction in Straumann Dysphagia Instrument (SDI) scores at week 10 20.

Reslizumab is associated with significant reductions in peak esophageal eosinophil levels (p < 0.0001), physician global assessments of eosinophils (p = 0.0313), and predominant symptom assessments (p = 0.0062) 7. It also showed improvements in Child Health Questionnaire scores 12.

Lirentelimab (AK002) demonstrated a significant reduction in peak esophageal intraepithelial eosinophil counts at week 24 (p < 0.0001) 10. Fluticasone Propionate was associated with a significant reduction in pediatric symptom scores over 12 weeks (p = 0.04) 11, though it did not show a statistically significant difference in histologic remission rates compared to other groups 11. Losartan Potassium showed evidence of histologic remission and reduced peak eosinophil counts in small cohorts [18, 19].

Recent results — preliminary, needs further review

  • AQ280 Capsule showed no clinically significant abnormalities in blood pressure or pulse rate during Phase 1 testing 2.

For the clinician treating this condition

  • CC-93538 shows statistically significant improvements in both dysphagia duration and eosinophil count reduction compared to placebo 9.
  • Dupilumab is associated with significant reductions in intraepithelial eosinophils and improved patient-reported dysphagia scores [8, 20].
  • Reslizumab demonstrates significant clinical improvement across multiple metrics including eosinophil levels and physician assessments 7.

AI synthesis of 9 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Dupilumab and cendakimab show moderate-to-high certainty benefit for dysphagia in eosinophilic esophagitis
Allergy & Immunology Sys. Review
Dupilumab and cendakimab show moderate-to-high certainty benefit for dysphagia in eosinophilic esophagitis New data shows different treatments for eosinophilic esophagitis symptoms
This network meta-analysis evaluates various treatments for eosinophilic esophagitis in adolescents and adults. The analysis indicates that …
New research identifies specific medications that help improve swallowing difficulties for adults and teens with eosinophilic esophagitis.
Sep 1, 2026
Narrative review on vitamin D and VDR in gastrointestinal and pulmonary diseases
Nutrition & Obesity Medicine Sys. Review
Narrative review on vitamin D and VDR in gastrointestinal and pulmonary diseases Vitamin D's Role in Gut and Lung Health Examined
This narrative review synthesizes evidence on vitamin D deficiency and VDR expression across gastrointestinal and pulmonary conditions. The …
A review explores how vitamin D deficiency and VDR expression may influence digestive and respiratory diseases, but more research is needed.
Frontiers May 18, 2026
Meta-analysis finds 2.31% EoE incidence with food allergen immunotherapy, none with aeroallergen SLIT
Allergy & Immunology Meta-analysis
Meta-analysis finds 2.31% EoE incidence with food allergen immunotherapy, none with aeroallergen SLIT Study finds link between food allergy treatment and rare swallowing condition
A systematic review and meta-analysis of 17 studies in patients receiving allergen immunotherapy found the incidence of confirmed eosinophil…
Food allergy treatment linked to rare swallowing condition in 2.3% of patients receiving food desensitization, while airborne treatments sho…
Apr 2, 2026